| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1117: Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency |
|
Medicine details |
|
| Medicine name | dostarlimab (Jemperli®) |
| Formulation | 500 mg concentrate for solution for infusion |
| Reference number | 5427 |
| Indication | Combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. |
| Company | GlaxoSmithKline UK |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/11/2025 |
| NICE guidance | |